Sino Biopharmaceutical Limited (Sino Biopharm) disclosed that on 21 April 2026 it repurchased 1.73 million ordinary shares on the Hong Kong Stock Exchange at prices ranging from HK$5.81 to HK$5.83 per share. The transaction involved total consideration of HK$10.06 million and all repurchased shares are earmarked for cancellation.
\n\nPost-transaction, the issued share capital stands unchanged at 18.75 billion shares, as the cancellation process has not yet been completed. The repurchase represents approximately 0.009% of the company’s issued shares outstanding prior to the buyback.
\n\nThe buyback was executed under the general mandate granted on 10 June 2025, which authorises repurchases of up to 1.88 billion shares. Cumulative purchases under this mandate now total 17.08 million shares, equivalent to 0.091% of the share count at the mandate date. In line with listing rules, Sino Biopharm is subject to a 30-day moratorium—ending 21 May 2026—on issuing new shares or transferring any treasury shares following the latest repurchase.
\n\nCompany Secretary Lai Kuen confirmed that the repurchase complied with all relevant Main Board Listing Rules and that no material changes have been made to the company’s previously filed explanatory statement.
Comments